Citius Pharmaceuticals (CTXR) Earnings Date, Estimates & Call Transcripts → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free CTXR Stock Alerts $0.69 -0.01 (-1.42%) (As of 05/10/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryLatest Earnings DateFeb. 14EstimatedActual EPS (Feb. 14) -$0.06 Missed By -$0.19 Consensus EPS (Feb. 14) $0.13 Get Citius Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for CTXR and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCTXR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CTXR Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. Citius Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($0.21) EPSNext Year EPS Consensus Estimate: $0.09 EPSCTXR Earnings Date and InformationCitius Pharmaceuticals last posted its quarterly earnings results on February 14th, 2024. The reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.13 by $0.19. Citius Pharmaceuticals has generated ($0.26) earnings per share over the last year (($0.26) diluted earnings per share). Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($0.21) to $0.09 per share. Read More Citius Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript2/14/2024Q1 2024$0.13($0.06)($0.19)($0.06)--12/29/2023Q4 2023($0.02)($0.07)($0.05)($0.07)--8/14/2023Q3 2023($0.06)($0.06)-($0.06)--5/12/2023Q2 2023($0.04)($0.07)($0.03)($0.07)--2/10/2023Q1 2023-($0.04)($0.04)($0.06)--12/22/2022Q4 2022($0.04)($0.05)($0.01)($0.05)-- Get the Latest News and Ratings for CTXR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/11/2022Q3 2022($0.05)($0.06)($0.01)($0.06)--5/12/2022Q2 2022($0.08)($0.05)+$0.03($0.05)--2/10/2022Q1 2022($0.06)($0.06)-($0.06)-- 12/15/2021Q4 2021($0.03)($0.03)-($0.03)--8/12/2021Q2 2021($0.05)($0.05)-($0.05)--5/13/2021Q1 2021($0.08)($0.04)+$0.04($0.04)-- Citius Pharmaceuticals Earnings - Frequently Asked Questions When did Citius Pharmaceuticals announce their last quarterly earnings? Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earning data on Wednesday, February 14, 2024. Learn more on CTXR's earnings history. Did Citius Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Citius Pharmaceuticals (NASDAQ:CTXR) missed the analysts' consensus estimate of $0.13 by $0.19 with a reported earnings per share (EPS) of ($0.06). Learn more on analysts' earnings estimate vs. CTXR's actual earnings. How much profit does Citius Pharmaceuticals generate each year? Citius Pharmaceuticals (NASDAQ:CTXR) has a recorded net income of -$32.54 million. CTXR has generated -$0.26 earnings per share over the last four quarters. What is Citius Pharmaceuticals's EPS forecast for next year? Citius Pharmaceuticals's earnings are expected to grow from ($0.21) per share to $0.09 per share in the next year. More Earnings Resources from MarketBeat Related Companies: Cartesian Therapeutics Earnings Karyopharm Therapeutics Earnings Societal CDMO Earnings GlycoMimetics Earnings Adicet Bio Earnings Repare Therapeutics Earnings PDS Biotechnology Earnings Amylyx Pharmaceuticals Earnings Immunic Earnings Abeona Therapeutics Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:CTXR) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
